尼妥珠单抗联合同期放化疗治疗局部晚期鼻咽癌的效果  

Curative Effect of Locally Advanced Nasopharyngeal Carcinoma by Nimotuzumab with Concurrent Chemotherapy and Radiotherapy

作　　者：郑俏聪 吴盛 林琪琪 张启红 谭茜茜 ZHENG Qiaocong;WU Sheng;LIN Qiqi;ZHANG Qihong;TAN Qianqian(The People’s Hospital of Yangjiang,Yangjiang 529500,China)

机构地区：[1]广东省阳江市人民医院,广东阳江529500

出　　处：《中国医学创新》2020年第30期1-5,共5页Medical Innovation of China

基　　金：阳江市科技局立项项目([2019]50号-23)。

摘　　要：目的:探讨尼妥珠单抗联合同期放化疗治疗局部晚期鼻咽癌的临床效果。方法:选择2017年6月-2019年1月于本院进行治疗的60例局部晚期鼻咽癌患者为研究对象。按照随机数字表对照法将其分为试验组和对照组,每组30例。对照组接受同期放化疗治疗,试验组接受尼妥珠单抗联合同期放化疗治疗。比较两组近期治疗效果和安全性。结果:试验组RR、DCR均高于对照组,差异均有统计学意义(P<0.05)。两组治疗期间骨髓抑制、皮肤损伤、口腔黏膜炎、消化道反应、肝功能异常发生率及严重程度比较,差异均无统计学意义(P>0.05)。随访期间试验组无病生存率高于对照组,差异有统计学意义(P<0.05);两组复发或远处转移率均为0,总生存率为100%,差异均无统计学意义(P>0.05)。结论:尼妥珠单抗能够提高同期放化疗治疗局部晚期鼻咽癌的近期效果,提高无病生存率,且不会明显增加不良反应。Objective:To explore the curative effect of locally advanced nasopharyngeal carcinoma by Nimotuzumab with concurrent chemotherapy and radiotherapy.Method:A total of 60 patients with locally advanced nasopharyngeal carcinoma treated in our hospital from June 2017 to January 2019 were selected as the research objects.According to the random number table control method,they were divided into experimental group and control group,30 cases in each group.The control group received concurrent chemotherapy and radiotherapy,and the experimental group received Nimotuzumab combined with concurrent chemotherapy and radiotherapy.The short-term effect and safety of the two groups were compared.Result:RR and DCR in the experimental group were higher than those in the control group,the differences were statistically significant(P<0.05).There were no statistically significant differences in the incidence and severity of bone marrow suppression,skin injury,oral mucositis,digestive tract reaction,liver dysfunction between the two groups during treatment(P>0.05).During follow-up,the disease-free survival rate in the experimental group was higher than that in the control group,the difference was statistically significant(P<0.05).The rates of recurrence or distant metastasis in two groups were 0,and the overall survival rate were 100%,there were no statistically significant differences(P>0.05).Conclusion:Nimotuzumab can improve the short-term efficacy of concurrent chemotherapy and radiotherapy in the treatment of locally advanced nasopharyngeal carcinoma,improve disease-free survival rate,and do not significantly increase adverse reactions.

关 键 词：局部晚期鼻咽癌 尼妥珠单抗 同期放化疗 不良反应 生存率 

分 类 号：R739.63[医药卫生—肿瘤]